Abstract
Inflammatory myofibroblastic tumor (IMT), a benign and rare neoplasm, of mesenchymal origin, pseudoarcomatous, is responsible for about 0.7% of all neoplastic presentations in the pulmonary region, being the most frequent cause of pulmonary nodules in pediatric patients, approximately 50% of the presentations. Thus, the present study aims to report a rare case of IMT in the lung site in a 31-year-old patient undergoing treatment for breast cancer, according to a literary review, relating the data according to the clinical presentation. Due to scarce documentation in the medical literature, no cases were found similar to the one described in relation to the reported oncological primary condition of the patient, making the present case a clinical challenge in modern medical practice.
Highlights
Inflammatory myofibroblastic tumor (IMT), a benign and rare neoplasm, of mesenchymal origin, pseudoarcomatous, is responsible for about 0.7% of all neoplastic presentations in the pulmonary region, being the most frequent cause of pulmonary nodules in pediatric patients, approximately 50% of the presentations
The present study aims to report a rare case of inflammatory myofibroblastic tumor (IMT) in the lung site in a 31-yearold patient undergoing treatment for breast cancer, according to a literary review, relating the data according to the clinical presentation
The inflammatory myofibroblastic tumor (IMT), a benign tumor characterized by diagnostic rarity, responsible for about 0.7% of all neoplastic presentations in the pulmonary region, being the most
Summary
Inflammatory myofibroblastic tumor (IMT), a benign and rare neoplasm, of mesenchymal origin, pseudoarcomatous, is responsible for about 0.7% of all neoplastic presentations in the pulmonary region, being the most frequent cause of pulmonary nodules in pediatric patients, approximately 50% of the presentations. The present study aims to report a rare case of IMT in the lung site in a 31-yearold patient undergoing treatment for breast cancer, according to a literary review, relating the data according to the clinical presentation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have